Researchers at UT Southwestern reported in the journal Nature Cancer that Talzenna (talazoparib) successfully shrank the tumors of breast cancer patients with mutations in the PALB2 gene.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe